MYDA Advisors LLC Buys New Stake in LifeMD, Inc. $LFMD

MYDA Advisors LLC bought a new stake in LifeMD, Inc. (NASDAQ:LFMD) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 150,000 shares of the company’s stock, valued at approximately $512,000. MYDA Advisors LLC owned 0.31% of LifeMD at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in LifeMD by 6.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,226,871 shares of the company’s stock valued at $15,120,000 after acquiring an additional 140,749 shares during the period. Federated Hermes Inc. increased its position in LifeMD by 278.1% in the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock valued at $3,343,000 after acquiring an additional 721,018 shares during the period. Geode Capital Management LLC increased its position in LifeMD by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 959,700 shares of the company’s stock valued at $3,273,000 after acquiring an additional 11,324 shares during the period. Royce & Associates LP increased its position in LifeMD by 11.7% in the 4th quarter. Royce & Associates LP now owns 909,651 shares of the company’s stock valued at $3,102,000 after acquiring an additional 95,200 shares during the period. Finally, Prescott Group Capital Management L.L.C. acquired a new stake in LifeMD in the 4th quarter valued at approximately $2,344,000. 35.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LFMD has been the topic of several analyst reports. Weiss Ratings upgraded LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Loop Capital set a $10.00 target price on LifeMD in a research report on Thursday, March 12th. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of LifeMD in a research report on Monday, May 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of LifeMD in a research report on Tuesday, March 10th. Finally, UBS Group reiterated a “buy” rating on shares of LifeMD in a research report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.14.

LifeMD Stock Performance

Shares of LFMD stock opened at $4.70 on Monday. LifeMD, Inc. has a 1 year low of $2.56 and a 1 year high of $15.84. The stock has a market cap of $227.29 million, a PE ratio of 94.02 and a beta of 1.98. The business’s fifty day moving average is $4.36 and its 200-day moving average is $3.80.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. The firm had revenue of $50.16 million for the quarter, compared to analyst estimates of $48.84 million. Equities research analysts predict that LifeMD, Inc. will post -0.37 earnings per share for the current year.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.